RESUMO
Objective:To study and design a disaster recovery backup system that not only can meet the continuous requirement of medical services but also can ensure data so as to achieve a data center plan that has maximum utilization ratio of resources. Methods: Face to the current situation of constructing data center of hospital, the cloud computing, virtualization technique, dual-active storage and database cluster were combined in the research, and through established calculation, storage, network, desktop and safety to finally achieve five private cloud included of producing cloud, testing cloud, disaster recovery cloud, desktop cloud and secure cloud. And then, based on above design to establish a plan about dual-active data center of private cloud included of recovery point objectives(RPO)=0 and recovery time objective(RTO)≈0.Results: This research has designed a dual-data center of private cloud with high availability, high performance, high expansion and high convenience management. It has realized simple and convenient management and operation for all data centers, and enhanced the utilization ratio of data resources.Conclusion: The dual-active data center of private cloud can farthest realize full use for resource and save investment and construction costs of IT infrastructure under the preconditions of meeting the continuous requirement of medical services.
RESUMO
Objective: To compare the pharmacokinetics and relative bioavailability of rapid oral disintegrating tablet of dimenhydrinate (RODTD) and those of market available tablet of dimenhydrinate (DMH). Methods: Eight healthy volunteers were evenly randomized into 2 groups, one group received RODTD (25 mg) and the other received available market tablet of dimenhydrinate (25 mg). The blood levels of DMH were determined by high performance liquid chromatography (HPLC) before and after drug administration in 2 groups. Chromatography conditions were: Nova-Pak C18 as chromatographic column, methanol triethylamine buffer (1 : 1),flow rate: 1.0 ml/min, detection wavelength: 225 nm, and room temperature. The pharmacokinetics and relative bioavailability of RODTD and market available tablets were investigated. Results: The standard curve of DMH in the blank plasma was linear within the range of 5-500 ng/ml, with the regression equation being C=0.004 4 A+4.745 and R2=0.996. The limit of detection was 2 ng/ml; the average recovery rate was (90.55±4.69)% and the RSD was 0.041%. The intra-day derivations of 3 different concentrations (low, middle, and high) of plasma were 9.27%, 4.93%, and 2.95%, respectively (n=5), and the inter-day derivations were 9.97%, 3.81%, and 3.06%, respectively (n=5). Blood samples (3 ml) were subjected to HPLC assay and significant difference was found between the 2 forms of DMH. The pharmacokinetic parameters of RODTD were: AUC=(602.04±113.82) ng • h • ml-1, Cmax=(95.86±21.28) ng • h • ml-1, and TPeak=(1.8±0.32) h; the pharmacokinetic parameters of market available tablets were: AUC=(342.73±84.96) ng • h • ml-1 Cmax=(46.34± 10.32) ng • ml-1, and TPeak=(2.65±0.24) h. Statistical analysis showed there was significant difference in the relative bioavailability of 2 forms of DMH(P<0.01). The relative bioavailability of RODTD to market tablet was 175.66%. Conclusion: The developed RODTD can obviously increase the relative bioavailability of DMH.